John Burke, MD

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.

CancerNetwork®sat down with John Burke, MD, to talk about the topline results in the KEYNOTE-564 trial, which examined the use of pembrolizumab in a population of patients with high-risk renal cell carcinoma.

CancerNetwork®sat down with John Burke, MD, to discuss why treatment with pembrolizumab post-surgery may be a promising option for patients with high-risk renal cell carcinoma.